Clinical trials: High-dose Chemotherapy
Lymphoma
SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00004031
- Testing
- rituximab, CHOP regimen, carmustine
- Where
- 15 sites in United States, Canada
- Volunteers
- 397 people
- Sponsor
- SWOG Cancer Research Network
Pediatric Solid Tumor
A Prediction Model of Hematological Recovery After High-dose Chemotherapy in Pediatric Solid Tumor
This study aims to compare and evaluate the predicted values of the participants, and the algorithm predicted values of ANC level reduction periods after high-capacity chemotherapy in pediatric solid tumor patients.
- Trial name
- NCT05024331
- Where
- South Korea
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Graft vs Host Disease
High Dose Chemotherapy and Autologous Transplant for Breast Cancer
To determine survival outcomes for patients with chemosensitive brest cancer after treatment with high dose chemotherapy
- Trial name
- NCT00186641
- Testing
- high dose chemo and auto hematopoietic cell transplant
- Where
- United States
- Volunteers
- 203 people
- Sponsor
- Stanford University
Mantle-cell Lymphoma
Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT
1. Primary endpoint: Time to relapse/progression (TTP) after achieving a complete or partial response with the (R-GemOxD)-induction therapy 2. Secondary endpoints: 1.
- Trial name
- MAN2 (NCT02267915)
- Testing
- subcutaneous Rituximab
- Where
- 15 sites in Spain
- Volunteers
- 36 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Cachexia
A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia
This open label ascending dose study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AV-380 in cancer patients with Cachexia.
- Trial name
- NCT05865535
- Testing
- AV-380
- Where
- 12 sites in United States
- Volunteers
- 30 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Newly Diagnosed Multiple Myeloma
Multiple Myeloma and Exercise
This study will establich the feasibility of weight lifting exercise among patients with multiple myeloma, determine if weight lifting exercise increases lean body mass among patients with multiple myeloma and obtain further…
- Trial name
- NCT01809717
- Testing
- Weight Lifting Exercises
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer, Leukemia
High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00060255
- Testing
- busulfan, carboplatin, carmustine
- Where
- United States
- Volunteers
- 451 people
- Sponsor
- Roswell Park Cancer Institute
Lymphoma
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and…
- Trial name
- NCT00005589
- Testing
- filgrastim, rituximab, carmustine
- Where
- 131 sites in Australia, Austria and 15 more
- Volunteers
- 460 people
- Sponsor
- EBMT Solid Tumors Working Party
Acute Myeloid Leukemia
Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission
This phase 2, open label, non-randomized study will evaluate the safety of administering high dose cytarabine (HiDAC) consolidation therapy on days 1-3 of each cycle, as compared to standard administration on days 1, 3, and 5 of…
- Trial name
- NCT04914676
- Testing
- Cytarabine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Florida
Cancer, Lymphoma
Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)
To evaluate whether palifermin (rHuKGF) administered as a single dose is non-inferior to 3 consecutive doses of palifermin in reducing the incidence of severe oral mucositis (World Health Organization [WHO] grade 3 and 4).
- Conditions
- Cancer, Lymphoma, Leukemia
- Trial name
- NCT00109031
- Testing
- palifermin, Total Body Irradiation, Cyclophosphamide
- Volunteers
- 47 people
- Sponsor
- Swedish Orphan Biovitrum
Hypertension, Cardiovascular Disease
Combination of OLMesartan and CCB or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study)
The purpose of this study is to investigate which combination therapy is more effective in reducing the incidence of cardiovascular events in Japanese elderly high-risk hypertensive patients: AT1 subtype angiotensin II receptor…
- Conditions
- Hypertension, Cardiovascular Disease, Diabetes
- Trial name
- NCT00454662
- Testing
- olmesartan medoxomil / amlodipine or azelnidipine, olmesartan medoxomil / low dose thiazide type drug
- Where
- Japan
- Volunteers
- 5,141 people
- Sponsor
- COLM Study Research Organization
Leukemia, Myelodysplastic Syndromes
Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Neutropenia
- Trial name
- NCT00002800
- Testing
- filgrastim, lintuzumab, cytarabine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Osteosarcoma
A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Limited Stage of High-grade Osteosarcoma
This is a Phase 1+2, open-label, dose-escalation, and multidose study, aiming to investigate the safety, tolerability and pharmacokinetics of ZKAB001 (a fully human monoclonal antibody targeting the Programmed Death - Ligand 1…
- Trial name
- NCT03676985
- Testing
- ZKAB001 5mg/kg, ZKAB001 10mg/kg, ZKAB001 15mg/kg
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Lee's Pharmaceutical Limited
Breast Cancer
Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy drugs and kill…
- Trial name
- NCT00002755
- Testing
- filgrastim, CMF regimen, cyclophosphamide
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 600 people
- Sponsor
- Scottish Cancer Therapy Network
Neuroblastoma
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Followed by Surgery and/or Radiation Therapy in Treating Young Patients With Advanced Neuroblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy drugs and kill…
- Trial name
- NCT00002740
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Children's Oncology Group
Hodgkin Lymphoma, Refractory
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients
To combine Brentuximab Vedotin with Dexamethasone, AraC and Cisplatin (DHAP) chemotherapy in patients with Hodgkin lymphoma (HL) refractory to first line chemotherapy or in first relapse is expected to induce a significantly…
- Conditions
- Hodgkin Lymphoma, Refractory, Relapse
- Trial name
- NCT02280993
- Testing
- DHAP, Brentuximab Vedotin, Autologous Peripheral Blood Stem Cell Transplantation
- Where
- 13 sites in Denmark, France and 2 more
- Volunteers
- 72 people
- Sponsor
- Marjolein Spiering
Gastroesophageal Reflux
Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI)
The purpose of this study is to determine the effect of vonoprazan compared to esomeprazole for preventing heartburn symptoms over a 4-week treatment period in participants who have a partial response to treatment with…
- Trial name
- NCT02743949
- Testing
- Vonoprazan, Esomeprazole
- Where
- 39 sites in Belgium, Bulgaria and 4 more
- Volunteers
- 256 people
- Sponsor
- Takeda
Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined…
- Conditions
- Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma
- Trial name
- NCT03418038
- Testing
- Ascorbic Acid, Carboplatin, Cisplatin
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- Mayo Clinic
Lymphoma
Comparing Autologous Peripheral Blood Stem Cell to Bone Marrow Transplantation for Recurrent Non-Hodgkin's Lymphoma
The purpose of this study is to evaluate the difference in relapse rates and long term event free survival in patients with intermediate grade or immunoblastic non-Hodgkin's lymphoma (NHL) whose marrow is not obviously involved…
- Trial name
- NCT00574626
- Testing
- PBSCT, Bone Marrow Transplant
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- University of Nebraska
Lymphoma, Non-Hodgkin
Tumor Lysate Pulsed-Dendritic Cell Vaccines After High-Dose Chemotherapy for Non-Hodgkin's Lymphoma
When patients relapse after primary chemotherapy for Non-Hodgkin's lymphoma, they may be eligible to receive high-dose chemotherapy with autologous stem cell support.
- Trial name
- NCT00006434
- Testing
- tumor-pulsed dendritic cells
- Where
- United States
- Sponsor
- National Center for Research Resources (NCRR)